SecBot SecBot
8-K ·Filed Oct 9, 2026

BRTX

BioRestorative Therapies, Inc.
NEUTRAL
Impact 2/10
Horizonweeks Processed17d 17h ago SEC0001213900-26-108467
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

Routine board appointment with no financial data — monitor next quarterly filing for any changes in governance or capital allocation strategy.

DirectionNeutral
Confidencehigh
Horizonweeks
Latest settled — T+5d
BRTX ▼ -8.57% at T+5d
NEUTRAL call -8.57% · α vs SPY -7.08% · entry $1.75 → $1.60
Next anchor: T+20d in 10d
Latest observation: T+7 -66.49% FF3 residual α
Entry = T+0 close
Oct 9, 2026
via day close
T+1d
-9.14%
call -9.14% · α -9.13%
$1.59
settled 15d ago
T+5d
-8.57%
call -8.57% · α -7.08%
$1.60
settled 11d ago
T+20d
Pending
in 10d
T+60d
Pending
in 2mo

Price Chart

Loading chart...

Executive Summary

BioRestorative Therapies appointed Donald J. Currie as a Class I independent director, effective October 7, 2026, filling the vacancy left by Katharyn Field's resignation on August 31, 2026. Mr. Currie, CEO of Hillcrest Energy Technologies, will serve on the Nominating and Corporate Governance and Compensation Committees, receiving CAD $2,000 per month in cash compensation. This is a routine board appointment with no material financial impact.

Key Facts

  • Donald J. Currie appointed as Class I director effective October 7, 2026
  • Fills vacancy from Katharyn Field's resignation effective August 31, 2026
  • Currie is independent director under Nasdaq listing rules and Rule 10A-3
  • Currie serves on Nominating and Corporate Governance and Compensation Committees
  • Compensation: CAD $2,000 per month cash fee, no standard non-employee director compensation program
  • No arrangements or family relationships with any director or executive officer
  • No transactions reportable under Item 404(a) of Regulation S-K

Financial Impact

Routine director appointment with CAD $2,000 per month cash fee — no material financial impact

Risk Factors

  • No material financial data in filing
  • No indication of strategic shift from appointment

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001213900-26-108467
Document: 0001213900-26-108467-index-headers.html0001213900-26-108467
Document: 0001213900-26-108467-index.html0001213900-26-108467
Document: 0001213900-26-108467.txt0001213900-26-108467
8 reports for BRTX
Performance horizon
75% Hit rate @ T+20 3 of 4 directional calls Went positive at some point 4 of 4 best @ T+60▲ +45.25%May 29, 2026
Filters
Rows
Reports for BRTX — sortable, filterable
TypeNow
Oct 9, 2026
17d ago
8-K
NEUTRAL ★ 2/10
$1.75awaiting T+20—$1.58 (−9.71%)
Sep 11, 2026
6w ago
8-K
BEARISH ★ 7/10
$2.67 $1.91▲ +28.46%▲ +30.33%$1.58 (+40.82%)
Sep 2, 2026
7w ago
Press Release
NEUTRAL ★ 4/10
$0.1437 $2.14▲ +1389.21%▲ +1389.67%$1.58 (+999.51%)
Aug 25, 2026
8w ago
8-K
BEARISH ★ 7/10
$0.2169 $2.51▼ −1057.22%▼ −1057.07%$1.58 (−628.45%)
Jun 12, 2026
19w ago
8-K
BEARISH ★ 6/10
$0.3910 $0.3400▲ +13.04%▲ +13.04%$1.58 (−304.09%)
May 29, 2026
21w ago
8-K
BEARISH ★ 6/10
$0.4064 $0.3760▲ +7.48%▲ +6.18%$1.58 (−288.78%)
May 1, 2026
25w ago
8-K
NEUTRAL ★ 3/10
$0.2420 $0.4064▲ +67.93%▲ +62.29%$1.58 (+552.89%)
Apr 7, 2026
29w ago
Press Release
NEUTRAL ★ 3/10
$0.2507 $0.2420▼ −3.47%▼ −13.25%$1.58 (+530.24%)
Showing 8 of 8

US Market Status

Market Closed — Opens in 25m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Oct 9, 2026